What does a diagnosis of prostate adenocarcinoma with Gleason score 3 + 4 indicate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Prostate Adenocarcinoma Gleason 3 + 4 = 7 (Grade Group 2)

A diagnosis of prostate adenocarcinoma with Gleason score 3 + 4 = 7 means you have intermediate-risk prostate cancer where the predominant (most common) pattern of cancer cells shows moderately abnormal architecture (pattern 3), with a smaller secondary component showing more aggressive, poorly formed glands (pattern 4). 1

What the Numbers Mean

  • The Gleason score is calculated by adding the two most common cancer patterns seen under the microscope, each graded from 1 (least aggressive) to 5 (most aggressive). 2, 3

  • In your case, "3 + 4" means:

    • Pattern 3 (moderately differentiated cells) is the dominant pattern, comprising the majority of your tumor 1
    • Pattern 4 (poorly formed, fused, or cribriform glands) is the secondary pattern, present in a smaller proportion 4

  • The total score of 7 places you in the intermediate-risk category, but the order matters critically: Gleason 3 + 4 = 7 has a significantly better prognosis than Gleason 4 + 3 = 7, because the primary pattern determines aggressiveness. 2, 1

Prognosis

  • Gleason 3 + 4 = 7 disease carries an excellent long-term outlook, with 10-year prostate-cancer-specific survival exceeding 92%. 1

  • The 5-year biochemical recurrence-free survival after radical prostatectomy is approximately 88% for favorable intermediate-risk patients. 1

  • Each increase in Gleason score correlates with greater tumor aggressiveness, and the presence of any pattern 4 component (versus pure pattern 3) significantly worsens prognosis. 2, 5

Risk Stratification: Favorable vs. Unfavorable Intermediate-Risk

Your Gleason 3 + 4 = 7 cancer is classified as intermediate-risk, but this category is further subdivided based on additional tumor characteristics: 1

Favorable Intermediate-Risk (ALL of the following must be present):

  • Primary Gleason pattern 3 (which you have: 3 + 4) 1
  • Less than 50% of biopsy cores contain cancer 1
  • Only one intermediate-risk factor (either PSA 10–20 ng/mL or clinical stage T2b-c, but not both) 1

Unfavorable Intermediate-Risk (ANY of the following):

  • ≥50% of biopsy cores positive for cancer 1
  • Multiple intermediate-risk factors (e.g., elevated PSA and advanced clinical stage) 1
  • Primary Gleason pattern 4 (i.e., Gleason 4 + 3, which you do not have) 1

Treatment Recommendations Based on Life Expectancy

If Life Expectancy < 10 Years:

  • Observation or active surveillance is appropriate, because definitive therapy often causes more harm than benefit when competing health risks are present. 1

If Life Expectancy ≥ 10 Years AND Favorable Intermediate-Risk:

  • Active surveillance is now an acceptable option if you are fully informed and agree to close monitoring (regular PSA testing and repeat biopsies every 1–2 years). 1

  • Radical prostatectomy with pelvic lymph-node dissection is recommended when the estimated risk of nodal involvement is ≥2%. 1

  • External-beam radiation therapy (EBRT) combined with 4–6 months of androgen-deprivation therapy (ADT) is a guideline-supported definitive option. 1

  • Brachytherapy alone or combined with EBRT is also acceptable. 1

If Life Expectancy ≥ 10 Years AND Unfavorable Intermediate-Risk:

  • Definitive treatment is strongly recommended; active surveillance is not appropriate. 1

  • Options include radical prostatectomy, EBRT ± ADT, or brachytherapy—the same modalities as favorable disease, but observation is excluded. 1

Common Pitfalls and Caveats

  • Biopsy sampling error: Approximately 24% of patients with Gleason 3 + 4 on biopsy are upgraded to primary pattern 4 or higher on final prostatectomy pathology, which worsens prognosis. 6

  • Grading variability: Non-genitourinary pathologists tend to assign higher Gleason scores than specialized genitourinary pathologists, with a tendency to overcall pattern 4. 7 Consider expert pathology review if treatment decisions are borderline.

  • Pattern 4 proportion matters: Even within Gleason 3 + 4 = 7, the percentage of pattern 4 present influences outcomes—higher proportions confer worse prognosis. 5

  • Not benign: Despite being "lower" intermediate-risk, Gleason 3 + 4 = 7 is true malignancy capable of infiltration, extraprostatic extension, and metastasis; it requires definitive management in patients with adequate life expectancy. 8

References

1
Guideline

Prognosis and Management of Gleason 3 + 4 = 7 (Grade Group 2) Prostate Cancer

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What are the treatment options for an 84-year-old male with prostate adenocarcinoma, Gleason score 4+3=7, involving 11 of 12 core biopsy samples?
What are the treatment options for a 77-year-old man with Gleason 6 (3+3) prostate adenocarcinoma involving 4 of 14 cores and focal high‑grade prostatic intra‑epithelial neoplasia (PIN) present in 3 of 12 cores?
A patient’s prostate biopsy shows Gleason Grade Group IV (Gleason score 8). What is the clinical stage of his prostate cancer and what are the appropriate treatment options?
For a patient with a prostate biopsy showing a positive core but a Gleason grade other than 6, what is the recommended management?
What is the best treatment approach for a 65-year-old male with End-Stage Renal Disease (ESRD) on dialysis and a Gleason score 8 prostate cancer with no evidence of metastasis?
What is the best antidepressant for a patient with chronic obstructive pulmonary disease who is depressed, constantly anxious, and wants a sedating medication that does not depress respiratory drive?
What SSRI is most appropriate for a COPD patient with depression and anxiety who wants mild sedation and wishes to avoid sertraline (Zoloft)?
What does a lymphocyte percentage of 12.5% (lymphopenia) and a monocyte percentage of 14.5% (monocytosis) on a complete blood count indicate, and what further work‑up is recommended?
What clinical stage corresponds to a prostate cancer with a Gleason score of 3 + 4 = 7?
Can you give a concise step‑by‑step protocol for a nurse practitioner to prescribe propranolol (a non‑selective β‑blocker) for performance anxiety during public speaking, including screening for contraindications, baseline vitals, dosing schedule, side‑effect counseling, alternative agents, and follow‑up?
What could cause blepharitis, nasal congestion, and cough persisting for several weeks?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.